24 month safety results of a randomized, multicenter, double-blind study of everolimus vs azathioprine in de novo heart transplant recipients.

被引：0
|
作者：
Eisen, H
Kobashigawa, J
Starling, RC
Cretin, N
Jaffe, J
Murphy, J
机构：
[1] Temple Univ, Philadelphia, PA 19122 USA
[2] Univ Calif Los Angeles, Los Angeles, CA 90024 USA
[3] Cleveland Clin Fdn, Cleveland, OH 44195 USA
[4] Novartis Pharmaceut, E Hanover, NJ USA
来源：
AMERICAN JOURNAL OF TRANSPLANTATION | 2004年 / 4卷
关键词：
D O I：
暂无
中图分类号：
R61 [外科手术学];
学科分类号：
摘要：
453
引用
收藏
页码：282 / 283
页数：2
相关论文
共 50 条
  • [1] Cyclosporin (CsA) profiles at months (M) 2 to 6 in a randomized, multicenter, double-blind study of everolimus vs. azathioprine in de novo heart transplant recipients.
    Eisen, HJ
    Mancini, D
    Vigano, M
    Kobashigawa, J
    Preiss, M
    [J]. AMERICAN JOURNAL OF TRANSPLANTATION, 2005, 5 : 244 - 244
  • [2] Evaluation of cyclosporin (CsA) profiles month 2 to 6 in an international phase III randomized, multicenter, double-blind study of everolimus in de novo heart transplant recipients
    Eisen, H. J.
    Mancini, D.
    Vigano, M.
    Kobashigawa, J.
    [J]. JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2005, 24 (02): : S89 - S89
  • [3] Efficacy and Safety of Everolimus in De Novo Liver Transplant Recipients-12 Month Results of a Randomized, Multicenter Study.
    Fung, J.
    Nevens, F.
    De Carlis, L.
    Metselaar, H. J.
    Beckebaum, S.
    Saliba, F.
    Jonas, S.
    Sudan, D.
    Fischer, L.
    Duvoux, C.
    Chavin, K. D.
    Jiang, H.
    Hexham, J. M.
    Junge, G.
    De Simone, P.
    [J]. LIVER TRANSPLANTATION, 2012, 18 : S109 - S110
  • [4] Everolimus (RAD) shows superiority over azathioprine to inhibit the decline of pulmonary function in stable lung transplant recipients - 24-month results of a multicenter, randomized, double-blind study.
    Valentine, VG
    Love, RB
    Snell, GI
    Vitulo, P
    Glanville, AR
    Pirron, U
    [J]. AMERICAN JOURNAL OF TRANSPLANTATION, 2004, 4 : 269 - 269
  • [5] Multicenter, randomized, double-blind, dose-finding study evaluating the efficacy and safety of RAD001 (RAD) in de novo renal transplant recipients.
    Kahan, BD
    Kaplan, B
    Lorber, M
    Winkler, M
    Cambon, N
    Maca, J
    Boger, R
    [J]. TRANSPLANTATION, 2000, 69 (08) : S359 - S359
  • [6] Efficacy of Everolimus with Reduced Cyclosporine in Japanese De Novo Renal Transplant Recipients: 24-Month, Randomized, Multicenter Study.
    Saito, K.
    Uchida, K.
    Takahara, S.
    Yoshimura, N.
    Teraoka, S.
    Cornu-Artis, C.
    Kobayashi, E.
    Takahashi, K.
    [J]. AMERICAN JOURNAL OF TRANSPLANTATION, 2013, 13 : 314 - 314
  • [7] Safety Events of Interest with the De Novo Use of Everolimus in Heart Transplant Recipients: 24-Month Analysis of the A2310 Study
    Lehmkuhl, H.
    Hirt, S.
    Rinaldi, M.
    Bara, C.
    Zuckermann, A.
    Lopez, P.
    Cines, M.
    Dong, G.
    Keogh, A.
    [J]. AMERICAN JOURNAL OF TRANSPLANTATION, 2012, 12 : 74 - 75
  • [8] Two year results of a double-blind, randomized, multicenter, international study of microemulsion vs oil-based cyclosporine in De Novo heart transplant patients
    Eisen, HJ
    Mueller, EA
    Mellein, B
    Hobbs, RE
    [J]. CIRCULATION, 1999, 100 (18) : 391 - 391
  • [9] Safety of Early Everolimus in De Novo Heart Transplant Recipients: Interim Analysis of the Randomized Study EVERHEART
    Potena, L.
    Barberini, F.
    Boffini, M.
    Amarelli, C.
    Pellegrini, C.
    Livi, U.
    Masciocco, G.
    Faggian, G.
    Gerosa, G.
    Lilla, P.
    Marraudino, N.
    Porcu, M.
    Guarisco, R.
    Maccherini, M.
    [J]. JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2013, 32 (04): : S136 - S136
  • [10] Cost-effectiveness of everolimus vs mycophenolate mofetil (MMF) in de novo heart transplant recipients.
    Tenderich, G
    Dorent, R
    Yang, XL
    Kessabi, S
    Ricci, JF
    Annemans, L
    [J]. AMERICAN JOURNAL OF TRANSPLANTATION, 2005, 5 : 251 - 251
12345